Locoregional immunochemotherapy in primary and metastatic liver disease: Meta-analysis and review of literature

Hepato-Gastroenterology

Volumn 50, Issue 53, 2003, Pages 1506-1510

  Kountouras, Jannis ^a,b   Zavos, Christos ^a   Chatzopoulos, Dimitrios ^a   Zavos, Nikolaos ^a   Boura, Panagiota ^a   Safioleas, Michael ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Department of Medicine ^*  (Greece)

Author keywords

Hepatocellular carcinoma; Immunochemotherapy; Locoregional; Meta analysis; Metastatic; Systemic

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MITOMYCIN C; MITOXANTRONE; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; FEVER; HUMAN; LIVER CANCER; LIVER FAILURE; LIVER METASTASIS; LUNG EMBOLISM; LYMPHOKINE ACTIVATED KILLER CELL; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METHODOLOGY; NAUSEA; NEUTROPENIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PUBLICATION; RECURRENT DISEASE; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; SURGICAL MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER DISEASES; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 0141428750     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Moradpour D, Wands JR: Molecular pathogenesis of hepatocellular carcinoma. In: Zakim D, Boyer TD (Eds.). Hepatology. Philadelphia: Saunders, 2003; pp. 1333-1354.
2. Kountouras J, Lygidakis NJ: New epidemiological data in liver oncogenesis. Hepatogastroenterology 2000; 47:855-861.
3. Kountouras J, Boura P, Kouklakis G: Locoregional immunochemotherapy in hepatocellular carcinoma. Hepatogastroenterology 2002; 49:1109-1112.
4. Kountouras J, Zavos C, Chatzopoulos D: Apoptosis in hepatocellular carcinoma. Hepatogastroenterology 2003; 50:242-249.
5. Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-285.
6. Lin TY, Lee CS, Chen KM, Chen CC: Role of surgery in treatment of primary carcinoma of the liver: a 31-year experience. Br J Surg 1987; 74:839-842.
7. Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12:1323-1334.
8. Di Carlo V, Ferrari G, Castoldi R, Nadalin S, Marenghi C, Molteni B, Taccagni G, Castrucci M: Surgical treatment and prognostic variables of hepatocellular carcinoma in 122 cirrhotics. Hepatogastroenterology 1995; 3:222-229.
9. Takayama T, Nakatsuka T, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Hirai Y, Makuuchi M: Function preserving segmentation of the cirrhotic liver. Hepatogastroenterology 1995; 4:415-417.
10. Lygidakis NJ: A new look in the management of unresectable primary hepatocellular carcinoma. Hepatogastroenterology 1992; 39:577-583.
11. Zieren HU, Mueller JM, Zieren S: Resection of colorectal liver metastasis in old patients. Hepatogastroenterology 1994; 1:34-37.
12. Gozzetti G, Mazziotti A, Jovine E, Grazi GL, Morganti M: Bisegmentectomy 5-8 for the removed of tumors of the 8th hepatic segment - a technical note. Hepatogastroenterology 1994; 3:214-216.
13. Ohwada S, Tanahashi Y, Kawashima Y, Satoh Y, Nakamura S, Kobayashi I, Ohya T, Ishikawa S, Ohtaki A, Iino Y, et al: Surgery for tumor thrombi in the right atrium and inferior vena cava of patients with recurrent hepatocellular carcinoma. Hepatogastroenterology 1994; 2:154-157.
14. Kemeny M: Regional chemotherapy for regional metastasis from colorectal cancer. Hepatogastroenterology 1992; 1:18-23.
15. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y: Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989; 10:349-353.
16. Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwasa Z, Yasutomi M: Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 1986; 58:1001-1006.
17. Lygidakis NJ, Stringaris K: Locoregional chemoimmunotherapy transplenic and transtumoral in vivo immunostimulation. Hepatogastroenterology 1996; 43:440-447.
18. Lygidakis NJ, Tsiliakos S, Talaat A, Matsakis G, Tepetes K: Multidisciplinary management of hepatocellular carcinoma. Hepatogastroenterology 1997; 44:268-273.
19. Lygidakis NJ, Pearl A: Metastatic liver disease - a review. Hepatogastroenterology 1997; 44:1484-1487.
20. Lygidakis NJ, Berberabe AE, Spentzouris N, Dedemadi G, Kalligas T, Loukas G, Sotiropoulou B: Targeting locoregional immunochemotherapy with new drugs in metastatic liver disease: a promising alternative. Hepatogastroenterology 1998; 45:2248-2251.
21. Lygidakis NJ, Spentzouris N, Dedemadi G: Resectional liver surgery in metastatic liver disease. Hepatogastroenterology 1998; 45:1034-1038.
22. Lygidakis NJ, Vlachos L, Raptis S, Rassidakis G, Balaskas C, Sgourakis G, Mourikis D, Kehagias D, Kittas C: Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival. Hepatogastroenterology 1999; 46:2216-2228.
23. Boura P, Kountouras J, Lygidakis NJ: Tumor immunity and immunotherapy. Hepatogastroenterology 2001; 48:1040-1044.
24. Lygidakis NJ, Stringaris K, Kokinis K, Lyberopoulos K, Raptis S: Loeoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study. Hepatogastroenterology 1996; 43:212-220.
25. Boura P, Kountouras J, Lygidakis NJ, Safioleas M, Aphinives P: Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters. Hepatogastroenterology 1999; 46:799-803.
26. Tepetes KN, Tsamantas AT, Felekouras ES, Salakou SG, Kavadias DD: Conversion of unresectable hepatoma to respectable. Report of a case and review of the literature. Hepatogastroenterology 2000; 47:1105-1109.
27. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J: Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001; 33:52-61.
28. Lygidakis NJ, Kosmidis P, Ziras N, Parissis J, Kyparidou E: Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 1995; 15:467-472.
29. Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H: Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 1995; 15:543-550.
30. Toh U, Sudo T, Kido K, Matono S, Sasahara H, Mine T, Tanaka T, Sueyoshi S, Fujita H, Shirouzu K, Yamana H: Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer. Int J Clin Oncol 2002; 7:372-375.
31. Lygidakis NJ, Sgourakis G, Vlachos L, Raptis S, Safioleas M, Boura P, Kountouras J, Alamani M: Metastatic liver disease of colorectal origin: the value of locoregional immunochemo-therapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001; 48:1685-1691.
32. Ueda Y, Yamagishi H, Tanioka Y, Fujiwara H, Fuji N, Itoh T, Fujiki H, Yoshimura T, Oka T: Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology 1999; 46(Suppl 1):1274-1279.
33. Lygidakis NJ, Safioleas M, Sgourakis G, Spentzouris N, Dedemadi G, Sotiropoulou P: Metastatic melanoma: transplenic immunostimulation - a new therapeutical alternative for an ever-challenging disease. Hepatogastroenterology 1999; 46:148-156.
34. Okuno K, Shigeoka H, Lee YS, Son E, Kayama H, Nakai T, Koh K, Yasutomi M: Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases. Hepatogastroenterology 1996; 43:688-691.
35. Lygidakis NJ, Ziras N, Parissis J: Resection versus resection combined with adjuvant pre- and post-operative chemotherapy - immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 1995; 42:155-161.
36. Lygidakis NJ, Savanis G, Pothoulakis J, Kapetanakis A: Transarterial locoregional immunostimulation and chemotherapy in patients with unresectable secondary liver tumours. Anticancer Res 1994; 14(2B):643-646.
37. Keilholz U, Schlag P, Tilgen W, Brado B, Galm F, Gorich J, Kauffmann GW, Moller P, Schneider S, Hunstein W: Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer 1992; 69:2172-2175.
38. Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K: Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 1992; 16:112-117.
39. Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y: Assessment of lymphokine-activated killer activity and y-interferon production in patients with small hepatocellular carcinomas. Hepatology 1993; 17:781-787.